Class information for:
Level 1: CHRONIC MYELOID LEUKEMIA//IMATINIB//NILOTINIB

Basic class information
ID Publications Average number
of references		 Avg. shr. active
ref. in WoS
384 3482 40.2 88%


Bar chart of Publication_year

Last years might be incomplete

Classes in level above (level 2)


ID, lev.
above		 Publications Label for level above
989 10020 CHRONIC MYELOID LEUKEMIA//IMATINIB//BCR ABL

Terms with highest relevance score


Rank Term Type of term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 CHRONIC MYELOID LEUKEMIA Author keyword 432 42% 23% 801
2 IMATINIB Author keyword 367 37% 23% 804
3 NILOTINIB Author keyword 330 70% 8% 273
4 DASATINIB Author keyword 233 54% 9% 304
5 BCR ABL Author keyword 142 31% 11% 388
6 CML Author keyword 105 25% 10% 364
7 IMATINIB MESYLATE Author keyword 78 30% 6% 216
8 IMATINIB RESISTANCE Author keyword 77 64% 2% 76
9 CYTOGENETIC RESPONSE Author keyword 65 70% 2% 54
10 T315I Author keyword 60 80% 1% 37

Web of Science journal categories

Author Key Words


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class		 LCSH search Wikipedia search
1 CHRONIC MYELOID LEUKEMIA 432 42% 23% 801 Search CHRONIC+MYELOID+LEUKEMIA Search CHRONIC+MYELOID+LEUKEMIA
2 IMATINIB 367 37% 23% 804 Search IMATINIB Search IMATINIB
3 NILOTINIB 330 70% 8% 273 Search NILOTINIB Search NILOTINIB
4 DASATINIB 233 54% 9% 304 Search DASATINIB Search DASATINIB
5 BCR ABL 142 31% 11% 388 Search BCR+ABL Search BCR+ABL
6 CML 105 25% 10% 364 Search CML Search CML
7 IMATINIB MESYLATE 78 30% 6% 216 Search IMATINIB+MESYLATE Search IMATINIB+MESYLATE
8 IMATINIB RESISTANCE 77 64% 2% 76 Search IMATINIB+RESISTANCE Search IMATINIB+RESISTANCE
9 CYTOGENETIC RESPONSE 65 70% 2% 54 Search CYTOGENETIC+RESPONSE Search CYTOGENETIC+RESPONSE
10 T315I 60 80% 1% 37 Search T315I Search T315I

Key Words Plus


Rank Web of Science journal category Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of publ.
in class
1 CYTOGENETIC RESPONSES 535 72% 12% 419
2 CHRONIC MYELOGENOUS LEUKEMIA 466 21% 56% 1939
3 CHRONIC PHASE 464 50% 19% 670
4 PATIENTS RECEIVING IMATINIB 384 87% 5% 186
5 CHRONIC MYELOID LEUKEMIA 339 19% 45% 1577
6 BCR ABL 246 28% 22% 757
7 DIAGNOSED CHRONIC PHASE 216 88% 3% 102
8 CLINICAL RESISTANCE 209 60% 7% 230
9 PHILADELPHIA CHROMOSOME 176 28% 16% 545
10 IMATINIB RESISTANT 172 69% 4% 146

Journals

Reviews


Title Publ. year Cit. Active references % act. ref.
to same field
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013 2013 153 137 96%
Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet 2009 462 110 97%
Standardized definitions of molecular response in chronic myeloid leukemia 2012 81 28 93%
BCR-ABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet 2011 99 80 99%
Laboratory recommendations for scoring deep molecular responses following treatment for chronic myeloid leukemia 2015 2 29 83%
The development of imatinib as a therapeutic agent for chronic myeloid leukemia 2005 653 134 71%
Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia 2007 272 74 88%
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet 2006 504 145 83%
Translation of the Philadelphia chromosome into therapy for CML 2008 284 86 63%
Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia 2007 271 72 82%

Address terms


Rank Address term Relevance score
(tfidf)		 Class's shr.
of term's tot.
occurrences		 Shr. of publ.
in class containing
term		 Num. of
publ. in
class
1 LEUKEMIA 46 14% 8.8% 305
2 HEMATOPOIESE LEUCEM CIBLE THER EUT 24 91% 0.3% 10
3 IMMUNE RECOVERY SECT 15 88% 0.2% 7
4 SECT EXPT HAEMATOL HAEMOPOIET STEM CELLS 15 88% 0.2% 7
5 MED UNIV KLIN 3 13 38% 0.8% 28
6 HEMATOL ONCOL LA SERAGNOLI 13 44% 0.6% 22
7 ONCOL HEMATOL CELL THER Y 12 63% 0.3% 12
8 HEMATOL UNIT HELSINKI 11 56% 0.4% 14
9 BMT LEUKEMIA 10 61% 0.3% 11
10 MED FAK MANNHEIM 10 16% 1.6% 55

Related classes at same level (level 1)


Rank Relatedness score Related classes
1 0.0000167129 C ABL//BCR ABL//BCR ABL ONCOPROTEIN
2 0.0000138984 PHILADELPHIA CHROMOSOME//CML//CHRONIC MYELOGENOUS LEUKEMIA
3 0.0000109029 OSI 420//OSI 774//CAKI 1 RENAL CELL CARCINOMA
4 0.0000075434 ORAL CHEMOTHERAPY//ORAL ANTICANCER AGENTS//ORAL ANTICANCER DRUGS
5 0.0000068979 CEPHALOTAXINE//HOMOHARRINGTONINE//CEPHALOTAXUS GRIFFITHII
6 0.0000068639 LEUKEMIA STEM CELLS//EXPT THER EUT TRANSLAT ONCOL PROGRAM//LEUKEMIC STEM CELL
7 0.0000067502 PRAME//LEUKEMIA ASSOCIATED ANTIGENS//UNIT 900
8 0.0000062686 LCK INHIBITOR//SRC INHIBITORS//SRC
9 0.0000044547 PDXP//SITEP PHASE UNIT 1//DIOC23
10 0.0000038282 CYCLIC THROMBOCYTOPENIA//CYCLICAL NEUTROPENIA//ACQUIRED AMEGAKARYOCYTIC THROMBOCYTOPENIA